Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C

Thomas R. O'Brien; Krystle A. Lang Kuhs; Ruth M. Pfeiffer

doi:10.1093/ofid/ofu110

Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C

Thomas R. O'Brien, Krystle A. Lang Kuhs, Ruth M. Pfeiffer

Research output: Contribution to journal › Article › peer-review

50 Scopus citations

Abstract

Treatment of hepatitis C virus (HCV) infection with ledipasvir/ sofosbuvir promises tremendous benefits, but high cost may impede implementation of this regimen. Subgroups with excellent response to 8 weeks of treatment might respond to a shorter course. In ION-3, 423 previously untreated HCV genotype 1-infected patients without cirrhosis had outcome data after receiving ledipasvir/sofosbuvir for 8 weeks. After reanalyzing published ION-3 data, we found that sustained virologic response (SVR) rates varied significantly by gender (P = .002) and rs12979860 genotype (P_trend = .03), exceeding 98% in women and rs12979860-CC individuals. The very high SVR rates in these subgroups suggest that these factors might be considered in selecting patients to receive 8 weeks of ledipasvir/sofosbuvir and support shorter trials of this regimen in selected patients.

Original language	English
Journal	Open Forum Infectious Diseases
Volume	1
Issue number	3
DOIs	https://doi.org/10.1093/ofid/ofu110
State	Published - Dec 1 2014

Bibliographical note

Publisher Copyright:
© The Author 2014.

Keywords

Clinical trial
Cost-effectiveness
Direct-acting antiviral agents
Gender
Hepatitis C virus
IFNL4

ASJC Scopus subject areas

Oncology
Clinical Neurology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/ofid/ofu110

Cite this

@article{d44d6eedb7e0416e9439eabdfd023bdf,

title = "Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C",

abstract = "Treatment of hepatitis C virus (HCV) infection with ledipasvir/ sofosbuvir promises tremendous benefits, but high cost may impede implementation of this regimen. Subgroups with excellent response to 8 weeks of treatment might respond to a shorter course. In ION-3, 423 previously untreated HCV genotype 1-infected patients without cirrhosis had outcome data after receiving ledipasvir/sofosbuvir for 8 weeks. After reanalyzing published ION-3 data, we found that sustained virologic response (SVR) rates varied significantly by gender (P = .002) and rs12979860 genotype (Ptrend = .03), exceeding 98% in women and rs12979860-CC individuals. The very high SVR rates in these subgroups suggest that these factors might be considered in selecting patients to receive 8 weeks of ledipasvir/sofosbuvir and support shorter trials of this regimen in selected patients.",

keywords = "Clinical trial, Cost-effectiveness, Direct-acting antiviral agents, Gender, Hepatitis C virus, IFNL4",

author = "O'Brien, {Thomas R.} and {Lang Kuhs}, {Krystle A.} and Pfeiffer, {Ruth M.}",

note = "Publisher Copyright: {\textcopyright} The Author 2014.",

year = "2014",

month = dec,

day = "1",

doi = "10.1093/ofid/ofu110",

language = "English",

volume = "1",

number = "3",

}

TY - JOUR

T1 - Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C

AU - O'Brien, Thomas R.

AU - Lang Kuhs, Krystle A.

AU - Pfeiffer, Ruth M.

N1 - Publisher Copyright: © The Author 2014.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Treatment of hepatitis C virus (HCV) infection with ledipasvir/ sofosbuvir promises tremendous benefits, but high cost may impede implementation of this regimen. Subgroups with excellent response to 8 weeks of treatment might respond to a shorter course. In ION-3, 423 previously untreated HCV genotype 1-infected patients without cirrhosis had outcome data after receiving ledipasvir/sofosbuvir for 8 weeks. After reanalyzing published ION-3 data, we found that sustained virologic response (SVR) rates varied significantly by gender (P = .002) and rs12979860 genotype (Ptrend = .03), exceeding 98% in women and rs12979860-CC individuals. The very high SVR rates in these subgroups suggest that these factors might be considered in selecting patients to receive 8 weeks of ledipasvir/sofosbuvir and support shorter trials of this regimen in selected patients.

AB - Treatment of hepatitis C virus (HCV) infection with ledipasvir/ sofosbuvir promises tremendous benefits, but high cost may impede implementation of this regimen. Subgroups with excellent response to 8 weeks of treatment might respond to a shorter course. In ION-3, 423 previously untreated HCV genotype 1-infected patients without cirrhosis had outcome data after receiving ledipasvir/sofosbuvir for 8 weeks. After reanalyzing published ION-3 data, we found that sustained virologic response (SVR) rates varied significantly by gender (P = .002) and rs12979860 genotype (Ptrend = .03), exceeding 98% in women and rs12979860-CC individuals. The very high SVR rates in these subgroups suggest that these factors might be considered in selecting patients to receive 8 weeks of ledipasvir/sofosbuvir and support shorter trials of this regimen in selected patients.

KW - Clinical trial

KW - Cost-effectiveness

KW - Direct-acting antiviral agents

KW - Gender

KW - Hepatitis C virus

KW - IFNL4

UR - http://www.scopus.com/inward/record.url?scp=84978328245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978328245&partnerID=8YFLogxK

U2 - 10.1093/ofid/ofu110

DO - 10.1093/ofid/ofu110

M3 - Article

AN - SCOPUS:84978328245

SN - 2328-8957

VL - 1

JO - Open Forum Infectious Diseases

JF - Open Forum Infectious Diseases

IS - 3

ER -

Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this